<DOC>
	<DOCNO>NCT02750345</DOCNO>
	<brief_summary>The purpose study determine whether Nitisinone 10 mg Tablets ( Test Product 1 ) Nitisinone 10 mg Tablets 'Baked ' 6 month @ 40Â°C/75 % RH ( Test Product 2 ) bioequivalent reference product Orfadin 10 mg hard capsule .</brief_summary>
	<brief_title>Bioequivalence Study Two Oral Nitisinone Formulations Treat Hereditary Tyrosinemia ( HT-1 )</brief_title>
	<detailed_description>The specific aim conduct randomize , single dose , three-period crossover bioequivalence study least 18 healthy male female subject single study center evaluate vivo performance two formulation Nitisinone 10 mg reference product Orfadin fasting . A total 24 healthy female male volunteer ( age 18 55 year old ) enter study . Volunteers determine free significant medical condition assess medical history , physical examination , blood urine test . Volunteers randomly allocate treatment sequence , administration investigational medicinal product ( IMP ) fast condition . There minimum 23 calendar day washout treatment . Blood sample collect pre-dose ( 0 hour ) 15 minute , 30 minute , 1 hour , 2 hour , 2 hour 30 minute , 3 hour , 3 hour 30 minute , 4 hour , 5 hour , 6 hour , 7 hour , 8 hour , 10 hour , 12 hour , 24 hour , 36 hour , 48 hour , 72 hour , 96 hour 120 hour post-dose ( total : 21 sample per treatment period ) .</detailed_description>
	<mesh_term>Tyrosinemias</mesh_term>
	<mesh_term>Nitisinone</mesh_term>
	<criteria>Healthy male female subject , 18 55 year ( inclusive ) signing informed consent . Body Mass Index ( BMI ) 18.5 30 kg/m2 ( inclusive ) . Body mass le 50 kg . Medical history , vital sign , physical examination , standard 12lead electrocardiogram ( ECG ) laboratory investigation must clinically acceptable within laboratory reference range relevant laboratory test , unless investigator considers deviation irrelevant purpose study . Nonsmokers . Females , : Of childbearing potential , follow condition meet : Negative pregnancy test If test positive , subject exclude study . In rare circumstance pregnancy discover subject receive IMP , every attempt must make follow term . Not lactate Abstaining sexual activity ( usual lifestyle subject ) must agree use accepted method contraception , agree continue method throughout study Examples reliable method contraception include nonhormonal intrauterine device , barrier method combine additional contraceptive method . In study concomitant use hormonal contraceptive NOT allow . Other method , consider investigator reliable , accepted . Written consent give participation study . Evidence psychiatric disorder , antagonistic personality , poor motivation , emotional intellectual problem likely limit validity consent participate study limit ability comply protocol requirement . Current alcohol use &gt; 21 unit alcohol per week male &gt; 14 unit alcohol per week female . Consumption 5 cup coffee ( equivalent amount caffeine ) per day . Regular exposure substance abuse ( alcohol ) within past year . Use medication , prescribe overthecounter herbal remedy , within 2 week first administration IMP except affect outcome study opinion investigator . In study concomitant use hormonal contraceptive NOT allow . Participation another study experimental drug , last administration previous IMP within 8 week ( within 10 elimination halflives chemical entity 2 elimination halflives antibody insulin ) , whichever long ) administration IMP study , discretion investigator . Treatment within previous 3 month first administration IMP drug welldefined potential adversely affect major organ system . A major illness 3 month commencement screening period . History hypersensitivity allergy IMP excipients related medication . History bronchial asthma bronchospastic disease . History convulsion . History porphyria . Relevant history laboratory clinical finding indicative acute chronic disease , likely influence study outcome . Donation loss blood equal exceed 500 mL 8 week first administration IMP . Diagnosis hypotension make screening period . Diagnosis hypertension make screening period current diagnosis hypertension . Resting pulse &gt; 100 beat per minute &lt; 40 beat per minute screening period , either supine standing . Positive test human immunodeficiency virus ( HIV ) , Hepatitis B Hepatitis C. Positive urine screen drug abuse . In case positive result urine screen drug abuse may repeat discretion investigator . Positive urine screen tobacco use . Positive pregnancy test . Female subject pregnant breastfeeding . Difficulty swallow . Any specific investigational product safety concern . Vulnerable subject , e.g . person detention . Subjects current keratopathy , clinically significant abnormality find slitlamp examination ( cataract ) discretion investigator . Concomitant use medication metabolize CYP2C9 ( ibuprofen , diclofenac indomethacin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HT-1</keyword>
	<keyword>Tyrosinemia</keyword>
	<keyword>Nitisinone</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>Food-Effect</keyword>
</DOC>